天目药业：关于子公司部分存货核销的公告

Core Viewpoint - Tianmu Pharmaceutical announced the write-off of certain inventory deemed to have no value, which will impact the company's pre-tax profit for Q3 2025 by approximately 2,596,957.33 yuan [1] Group 1 - The write-off is based on a principle of prudence, indicating a cautious approach by the company [1] - The affected inventory belongs to Tianmu Mountain Health Technology (Shenzhen) Co., Ltd., a wholly-owned subsidiary of Tianmu Pharmaceutical [1] - Investors are advised to pay attention to investment risks associated with this write-off [1]